Lawmakers Question Ethics of US Drug Trials in China

Bipartisan group raises concerns over intellectual property and forced participation of Uyghurs in clinical trials.

US biopharmaceutical companies have conducted hundreds of clinical trials in China over the past decade.
Trials involved collaboration with Chinese military-run hospitals, including those in Xinjiang.
Lawmakers cite risks of intellectual property theft and data trustworthiness issues.
Concerns include potential forced participation of Uyghurs in Xinjiang trials.
FDA has been asked to review and respond to these issues by October 1.